<DOC>
	<DOCNO>NCT01825837</DOCNO>
	<brief_summary>This extension study consist 2 part . In Part I , participant receive open-label treatment BIA 2-093 900 mg daily 2 week . Part II follow double-blind , parallel-group design participant randomly assign treatment BIA 2-093 300 mg , 900 mg , 1800 mg daily . Patients stable remission continue double-blind therapy approximately 6 month last patient enter Part II .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Eslicarbazepine Acetate Recurrence Prevention Bipolar I Disorder</brief_title>
	<detailed_description>The occurrence new manic/depressive episode consider treatment failure , patient discontinue study . At end Part II , 6 month last patient enrol longer approximately 15 month , patient still remission investigational product well-tolerated , patient option enter long-term open-label treatment dosage use Part II new episode occur , marketing authorize , clinical development BIA 2-093 recurrence prevention indication discontinue . If patient enter long-term treatment , establish recurrence prevention medication prescribe , BIA 2-093 taper ( patient assign 1800 mg daily dose decreased 900 mg 6 day ; assign 900 mg 300 mg receive placebo 6 day ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>sign Informed consent form ( ICF ) complete 3week treatment period Protocol identification number SCO/BIA2093203 Protocol identification number PRA/BIA2093204 show response treatment , define â‰¥ 50 % improvement Young Mania Rating Scale ( YMRS ) total score YMRS total score &lt; 12 present serum pregnancy test ( case woman childbearing potential ) consistent nongravid state use doublebarrier contraception throughout study relevant electrocardiogram ( ECG ) laboratory abnormality uncontrolled clinically relevant disorder uninsured capability comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>bipolar I disorder</keyword>
	<keyword>Eslicarbazepine acetate</keyword>
	<keyword>BIA 2-093</keyword>
</DOC>